Litigation hurts.

Shares in Indivior are down 11 per cent in early trading after the UK pharmaceutical company earlier revealed a 57 per cent drop in operating profit in 2016 after taking an impairment relating to its ongoing legal issues in the US.

The addiction drug specialist, which was spun off from Reckitt Benckiser in 2014, also warned that the final cost of the litigation could be “materially higher” than the $220m reserve it had put aside so far.

Get alerts on Indivior PLC when a new story is published

Copyright The Financial Times Limited 2021. All rights reserved.
Reuse this content (opens in new window)

Comments have not been enabled for this article.

Follow the topics in this article